Popular Filters
Trials for Bone Cancer Patients
Liquid Biopsy for Bone Cancer
This trial is testing a blood test that looks for small pieces of tumor DNA in patients with Ewing sarcoma or osteosarcoma. The goal is to see if this test can help predict if the cancer will return after treatment. A group of patients will participate to help researchers understand how useful this test can be.
Alkylating agent
Lurbinectedin for Ewing Sarcoma
This trial is testing a medication called lurbinectedin in children and young adults who have already been treated for solid tumors or have a type of cancer called Ewing sarcoma that has come back or didn't respond to other treatments. The medication aims to stop cancer cells from growing and spreading. The study will check if the treatment is safe and effective.
Monoclonal Antibodies
LY2880070 + Gemcitabine for Ewing Sarcoma
This trial is testing whether a new drug, LY2880070, combined with the chemotherapy drug gemcitabine, can effectively treat Ewing sarcoma or Ewing-like sarcoma. These cancers are tough to treat, and the combination aims to stop cancer cells from growing and dividing more effectively than current treatments. Gemcitabine is an active drug in advanced breast cancer both as a single agent and in combination with other chemotherapeutic agents.
Topoisomerase I inhibitor
Onivyde + Talazoparib/Temozolomide for Ewing Sarcoma
This trial is testing 2 combinations of therapy in children and young adults with recurrent or refractory solid tumors. The first part of the trial will determine the highest doses of the medications that can be given safely. The second part of the trial will test to see if the tumors go away in children and young adults with Ewing sarcoma.
Alkylating agents
Trabectedin + Irinotecan for Ewing Sarcoma
This trial is testing if trabectedin and irinotecan can treat Ewing's sarcoma that has a EWS-FLI1 mutation. Patients will get an infusion of 18F-FLT and have a PET scan to see if the treatment is working.
Trials for Rhabdomyosarcoma Patients
Vinca alkaloids
PEN-866 + Chemotherapy for Sarcoma
This trial is studying the combination of 3 drugs to see if it can be used to treat adolescents and young adults with solid tumors, Ewing sarcoma, or rhabdomyosarcoma that returned after or did not respond to standard treatments.
Procedure
DW-MRI for Sarcoma in Young Patients
This trial is testing whether a method that doesn't involve radiation (DW-MRI) can be used instead of current methods (CT, nuclear bone scan, PET-CT) to measure how well children with sarcomas are responding to therapy, in order to reduce exposure to harmful effects of ionizing radiation.
Topoisomerase I inhibitor
Onivyde + Talazoparib/Temozolomide for Ewing Sarcoma
This trial is testing 2 combinations of therapy in children and young adults with recurrent or refractory solid tumors. The first part of the trial will determine the highest doses of the medications that can be given safely. The second part of the trial will test to see if the tumors go away in children and young adults with Ewing sarcoma.
Trials With No Placebo
Alkylating Agent
Abemaciclib + Chemotherapy for Sarcoma
This trial is testing whether adding a new drug called abemaciclib to standard cancer treatments can help children and young adults with Ewing's sarcoma that has come back or did not respond to previous treatments. Abemaciclib works by blocking proteins that help cancer cells grow, which may slow down or stop the tumor. Participation could last several months or more, depending on individual responses.
Vinca alkaloids
PEN-866 + Chemotherapy for Sarcoma
This trial is studying the combination of 3 drugs to see if it can be used to treat adolescents and young adults with solid tumors, Ewing sarcoma, or rhabdomyosarcoma that returned after or did not respond to standard treatments.
Procedure
DW-MRI for Sarcoma in Young Patients
This trial is testing whether a method that doesn't involve radiation (DW-MRI) can be used instead of current methods (CT, nuclear bone scan, PET-CT) to measure how well children with sarcomas are responding to therapy, in order to reduce exposure to harmful effects of ionizing radiation.
View More Related Trials
Frequently Asked Questions
Introduction to ewing sarcoma
What are the top hospitals conducting ewing sarcoma research?
Ewing sarcoma, a rare and aggressive form of bone cancer that primarily affects children and young adults, has sparked the dedication of several top hospitals in their relentless pursuit for effective treatments. In Los Angeles, Children's Hospital leads the charge with seven active clinical trials focused on Ewing sarcoma, building on their impressive track record of 33 completed trials since undertaking their first study in 2001. Similarly, Johns Hopkins All Children's Hospital in Saint Petersburg is making significant strides with seven ongoing trials and 24 previous investigations since embarking on Ewing sarcoma research in 2007.
Across the country in Cincinnati, Cincinnati Children's Hospital Medical Center stands strong as another leading institution committed to combating this challenging disease. With seven active trials and a remarkable history of 35 completed studies since launching their inaugural Ewing sarcoma trial in 2001, they emphasize the importance of advancing our understanding and treatment options. Meanwhile, at Children's National Medical Center in Washington D.C., six ongoing clinical trials are underway alongside an impressive total of 31 prior Ewing sarcoma investigations dating back to their first recorded trial also conducted in 2001.
Last but certainly not least among these prestigious institutions is St. Jude Children's Research Hospital located within Memphis. While currently conducting five active Ewing sarcoma trials, St. Jude has accumulated valuable knowledge from its past seventeen studies initiated way back during the same year—2001—a testament to unwavering commitment towards finding answers for those affected by this devastating condition.
Together, these renowned hospitals illustrate both teamwork and determination that permeate across locations nationwide when it comes to fighting against Ewing sarcoma—an embodiment of hope for patients battling this disease while inspiring optimism for advancements yet to come
Which are the best cities for ewing sarcoma clinical trials?
When it comes to ewing sarcoma clinical trials, several cities are at the forefront of research and advancements. Los Angeles, California leads with 18 active trials focusing on treatments like Doxorubicin Hydrochloride, CAB-AXL-ADC, and Abemaciclib. New york, New York closely follows with 16 ongoing studies exploring INBRX-109, Vemurafenib, Palbociclib, among others. Boston, Massachusetts also plays a significant role in research with 14 active trials investigating Olaparib, Doxorubicin Hydrochloride, Vemurafenib. Furthermore Washington DC and Orlando each have 12 active trials studying different treatment approaches for this rare cancer type. These cities serve as hubs for cutting-edge clinical trials that offer hope and potential breakthroughs for those affected by ewing sarcoma.
Which are the top treatments for ewing sarcoma being explored in clinical trials?
In the realm of Ewing sarcoma, clinical trials are shedding light on promising treatments that offer new hope for patients. Leading the charge is seclidemstat, currently being explored in two active trials dedicated to this rare bone cancer. Also showing potential is abemaciclib, which has caught researchers' attention with one ongoing trial and a total of two all-time studies focused on Ewing sarcoma since its introduction in 2016. Additionally, LY2880070 and PEN-866 are making their mark as they undergo testing in one active trial each, marking important milestones in the fight against this aggressive disease. These breakthroughs underscore the dedication of scientists working tirelessly to improve outcomes for Ewing sarcoma patients everywhere.
What are the most recent clinical trials for ewing sarcoma?
Promising advancements are being made in clinical trials for Ewing sarcoma, offering hope to those affected by this rare bone and soft tissue cancer. One such trial focuses on evaluating the effectiveness of a treatment specifically designed for Ewing sarcoma patients. This Phase 1 and Phase 2 study became available on July 27, 2023, aiming to determine its potential benefits in improving outcomes. Additionally, another trial focused on dose selection within the initial phase of treatment is currently underway since May 23, 2023. These significant developments bring us closer to finding more effective therapies against Ewing sarcoma and ultimately improving patient prognosis.
What ewing sarcoma clinical trials were recently completed?
Recently, several clinical trials for Ewing sarcoma have reached completion, representing significant advances in the search for effective treatments. In December 2020, the Dana-Farber Cancer Institute concluded a trial investigating Cabozantinib's potential against this aggressive cancer. Likewise, in December 2019, another trial sponsored by the same institute explored Palbociclib's efficacy. Furthermore, David Wald conducted a study on ALT803 that finished in May 2018 and Washington University School of Medicine examined pegylated arginine deiminase around the same time frame. Lastly, Eisai Inc.'s investigation into Eribulin mesylate was completed in April 2018. These trials underscore ongoing efforts to combat Ewing sarcoma and bring hope to patients battling this condition.